LCID
Lucid Group, Inc.
LCID offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
TRS
TriMas Corporation
TRS has the edge over LCID overall, supported by stronger valuation and lower modeled downside.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
TRS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| Under pressure | |
| Strong |
TRS's profitability and balance sheet are currently healthy, but its revenue and cash flow are under pressure.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
TRS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.6x | $37.62 | — |
| Cheap | 12x | $286 | +661% |
| Forward | 19x | $37.62 | — |
| Fair | 21x | $504 | +1238% |
| Expensive | 33x | $795 | +2012% |
Historical ranges are pointers, not guarantees.
TRS's PE is in its cheap range at 1.6x. On analysts' estimates for next year's earnings, today's price would be 19x.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
TRS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect TRS's earnings to grow and its profitability to improve, with its revenue holding steady.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
TRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.03 | -92% |
| Q2 2026 | $24.03 | +2541% |
| Q1 2026 | $24.07 | +3026% |
| Q4 2025 | $2.97 | +403% |
| Q3 2025 | $1.08 | +69% |
| Q2 2025 | $0.91 | -7.1% |
| Q1 2025 | $0.77 | -21% |
| Q4 2024 | $0.59 | -39% |
| Q3 2024 | $0.64 | -48% |
TRS has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over TRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
TRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $174.6M | -36% |
| Q1 2026 | $168.3M | -30% |
| Q4 2025 | $155.5M | -32% |
| Q3 2025 | $269.3M | +17% |
| Q2 2025 | $274.8M | +14% |
| Q1 2025 | $241.7M | +6.4% |
| Q4 2024 | $228.1M | +8.8% |
| Q3 2024 | $229.4M | -2.5% |
TRS's revenue has slid since its 2025 peak: $175M last quarter, down 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 6.2% | -3.6 points |
| Q1 2026 | 4.1% | -4.9 points |
| Q4 2025 | -16% | -19 points |
| Q3 2025 | 6.2% | +2.6 points |
| Q2 2025 | 9.9% | +2.4 points |
| Q1 2025 | 9% | +3.5 points |
| Q4 2024 | 3.8% | -1.8 points |
| Q3 2024 | 3.6% | -6.5 points |
TRS has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
TRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$45M | -440% |
| Q1 2026 | -$24.6M | -$20.9M |
| Q4 2025 | $36.8M | +204% |
| Q3 2025 | $22.8M | +125% |
| Q2 2025 | $13.2M | +76% |
| Q1 2025 | -$3.8M | +$13.2M |
| Q4 2024 | $12.1M | +6.7% |
| Q3 2024 | $10.2M | -52% |
TRS has the edge over LCID on cash flow, with more consistent year-over-year improvement.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
TRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -1.2M shares |
| 1 year | -12% | -4.7M shares |
| 3 years | -13% | -5.4M shares |
| 5 years | -16% | -7.1M shares |
| Available history | -20% | -9.2M shares |
TRS has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $18.9M |
| Q1 2026 | $54.5M |
| Q4 2025 | $101.1M |
| Q3 2025 | — |
| Q2 2025 | $1.8M |
| Q1 2025 | $460,000 |
| Q4 2024 | — |
| Q3 2024 | $2.4M |
TRS spent $175M buying back its own shares over the past year, more than ten times what it spent the year before.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TRS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -14.4x | Net Cash |
| Q1 2026 | -11.5x | Net Cash |
| Q4 2025 | 4.5x | High |
| Q3 2025 | 2.7x | Moderate |
| Q2 2025 | 3.0x | Elevated |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | 3.4x | Elevated |
| Q3 2024 | 3.6x | Elevated |
TRS has more cash than debt.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
TRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 27.0 | Neutral |
TRS's weekly RSI is 45 (neutral) and its Stochastic is 27 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
TRS PE vs Consumer Cyclical Sector
| Metric | TRS | Sector median | Relative |
|---|---|---|---|
| PE | 1.6x | 18x | 91% below |
| PE % | 0 | 47 | 47 pts below |
TRS is trading at 1.6x earnings, a 91% discount to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
TRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $38.6 | 2.6% below |
| 20 week MA | $39.4 | 4.4% below |
| 50 week MA | $38.2 | 1.5% below |
| 100 week MA | $33.6 | 12% above |
| 200 week MA | $29.9 | 26% above |
TRS has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
TRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $31.2 | $32.0 | +2.6% |
| 2021 | $32.0 | $34.8 | +8.5% |
| 2022 | $34.8 | $27.8 | -20% |
| 2023 | $27.8 | $25.3 | -8.7% |
| 2024 | $25.3 | $24.6 | -3% |
| 2025 | $24.6 | $36.1 | +47% |
| 2026 YTD | $36.1 | $37.6 | +4.1% |
TRS has the edge over LCID on returns for 2026, with the stronger performance.